The 10 mg Mounjaro/Zepbound group experienced an average weight reduction of 13.4% or 29.8 lbs, which was over four times more weight loss than the placebo group
Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study
Common side effects reported in clinical trials include: Gastrointestinal disturbances : cramping, diarrhoea, flatulence, constipation, and abdominal discomfort are the most frequently reported adverse effects, occurring in up to 30% of users in some studies Nausea : particularly when starting treatment or taking higher doses These effects are typically mild to moderate and often improve with continued use or dose reduction Less common but important considerations : Berberine may cause a temporary increase in bilirubin levels, which could be problematic in individuals with liver disease Berberine should not be used during pregnancy or breastfeeding due to potential risks to the foetus or infant (including theoretical risk of kernicterus in infants) Berberine is not recommended for use in children or adolescents Allergic reactions, whilst rare, can occur Significant drug interactions are a major concern: Diabetes medications : Berberine may have additive glucose-lowering effects, particularly with insulin and sulphonylureas, increasing the risk of hypoglycaemia
Research from Umm Al-Qura University emphasizes the cardioprotective benefits of GLP-1 receptor agonists, along with their low risk of causing hypoglycemia, underscoring their value in a well-rounded approach to reducing cardiovascular disease
How IV Therapy Enhances Skin Health Our skin is the bodys largest organand its constantly under stress from environmental factors, diet, aging, and lifestyle
Medicine (Baltimore) 65(3):163-72
